Richard Bertz

Richard Bertz

UNVERIFIED PROFILE

Are you Richard Bertz?   Register this Author

Register author
Richard Bertz

Richard Bertz

Publications by authors named "Richard Bertz"

Are you Richard Bertz?   Register this Author

55Publications

930Reads

32Profile Views

Pharmacological Optimization for Successful Traumatic Brain Injury Drug Development.

J Neurotrauma 2019 Apr 10. Epub 2019 Apr 10.

2 Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Princeton, New Jersey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/neu.2018.6295DOI Listing
April 2019

Challenges and Opportunities With Oncology Drug Development in China.

Clin Pharmacol Ther 2019 Feb 8;105(2):363-375. Epub 2018 Mar 8.

Bristol-Myers Squibb, Princeton, New Jersey, USA.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1017
Publisher Site
http://dx.doi.org/10.1002/cpt.1017DOI Listing
February 2019

Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.

Clin Pharmacokinet 2018 08;57(8):911-928

Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ, 08540, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-017-0624-3DOI Listing
August 2018

Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.

Clin Pharmacokinet 2017 10;56(10):1173-1183

Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0504-2DOI Listing
October 2017

Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution.

Clin Pharmacol Drug Dev 2017 Mar;6(2):195-200

Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.315DOI Listing
March 2017

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.

J Clin Pharmacol 2017 02 23;57(2):235-246. Epub 2016 Aug 23.

Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Hopewell, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.798DOI Listing
February 2017

Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations.

Clin Pharmacokinet 2016 12;55(12):1559-1572

Bristol-Myers Squibb, Route 206 & Province Line Road, Lawrenceville, NJ, 08648, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-016-0420-5DOI Listing
December 2016

A Review of Daclatasvir Drug-Drug Interactions.

Adv Ther 2016 11 23;33(11):1867-1884. Epub 2016 Sep 23.

Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-016-0407-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083780PMC
November 2016

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.

Antivir Ther 2015 5;20(5):535-43. Epub 2015 Feb 5.

Bristol-Myers Squibb Research and Development, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP2941DOI Listing
May 2016

Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.

Clin Pharmacokinet 2015 Dec;54(12):1205-22

Research and Development, Bristol-Myers Squibb, P O Box 4000, Princeton, NJ, 08543-4000, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-015-0299-6DOI Listing
December 2015

The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.

Antivir Ther 2015 7;20(1):29-37. Epub 2014 Apr 7.

Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP2773DOI Listing
November 2015

Comparison of different QT interval correction methods for heart rate and QT beat-to-beat method in a thorough QT study of triple monoamine reuptake inhibitor BMS-820836.

J Clin Pharmacol 2015 Oct 9;55(10):1137-46. Epub 2015 Jun 9.

Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.528DOI Listing
October 2015

Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development.

Front Pharmacol 2014 10;5:247. Epub 2014 Nov 10.

Clinical Pharmacology and Pharmacometrics, Exploratory Clinical and Translational Research, Bristol-Myers Squibb , Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2014.00247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226160PMC
November 2014

Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.

Clin Pharmacol Drug Dev 2013 Oct 16;2(4):316-27. Epub 2013 Aug 16.

Bristol-Myers Squibb, Research and Development, Hopewell, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.52DOI Listing
October 2013

Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review.

Antivir Ther 2013 26;18(3):361-75. Epub 2012 Nov 26.

Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP2473DOI Listing
September 2013

Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Antimicrob Agents Chemother 2011 Dec 19;55(12):5746-52. Epub 2011 Sep 19.

Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Princeton, New Jersey 08543, USA.

View Article

Download full-text PDF

Source
http://aac.asm.org/lookup/doi/10.1128/AAC.00554-11
Publisher Site
http://dx.doi.org/10.1128/AAC.00554-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232801PMC
December 2011

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

J Antimicrob Chemother 2011 Sep 28;66(9):2075-82. Epub 2011 Jun 28.

Bristol-Myers Squibb, PO Box 5400, Princeton, NJ 08543-5400, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkr266DOI Listing
September 2011

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

Antivir Ther 2010 ;15(8):1107-14

Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, R&D, Hopewell, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP1673DOI Listing
April 2011

Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.

J Clin Pharmacol 2011 Mar 10;51(3):368-77. Epub 2010 May 10.

Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, 311 Pennington-Rocky Hill Rd., Pennington, NJ 08534, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270010367651
Publisher Site
http://dx.doi.org/10.1177/0091270010367651DOI Listing
March 2011

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.

J Clin Pharmacol 2009 Jun 24;49(6):700-9. Epub 2009 Apr 24.

Bristol-Myers Squibb Company, Mailstop: 8A-1.19, 311 Pennington-Rocky Hill Road, Hopewell, NJ 08534, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270009333854
Publisher Site
http://dx.doi.org/10.1177/0091270009333854DOI Listing
June 2009

Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.

Pharmacogenetics 2004 May;14(5):279-84

Department of Pharmacogenetics, Abbott Laboratories, Abbott Park, Illinois 60064-6217, USA.

View Article

Download full-text PDF

Source
May 2004

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

J Infect Dis 2004 Jan 7;189(2):265-72. Epub 2004 Jan 7.

Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1086/380799DOI Listing
January 2004

Protein binding in antiretroviral therapies.

AIDS Res Hum Retroviruses 2003 Sep;19(9):825-35

St. Stephens Centre, Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/088922203769232629DOI Listing
September 2003